TIGIT and myeloid sarcoma: These findings support our hypothesis that TIGIT+ B cells could suppress the proliferation of predominantly CCR6+ cTfh cells and that impairment of TIGIT expression on B cells alters the distribution of cTfh cells in patients with MS (Supplemental Figure 8).